TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21718471
Drug: 6 month
Normalized name: LEUPROLIDE (CAMCEVI) 42MG (6 MONTH) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 month intensive inpatient treatment program during weekdays, followed by six monthly return visits of 2 days (Group A)
Study: 21718471
Drug: 2 month
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 month intensive inpatient treatment program during weekdays, followed by biweekly return visits of 2 days during the next four months, followed by six monthly return visits of 2 days (Group B)
Study: 2643237
Drug: Valaxon tablets
Normalized name: MALAOXON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaxon tablets
Study: 2643237
Drug: Valium tablets
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valium tablets
Study: 27347034
Drug: Piperazine ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules
Study: 27347034
Drug: Conservative or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative or hormone therapy
Study: 22413874
Drug: DRV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r monotherapy (strict ITT analysis)
Study: 20801496
Drug: 110 mg
Normalized name: lactase 110 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 mg dabigatran
Study: 20801496
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dabigatran
Study: 9647138
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (30,000 KIU/kg)
Study: 9647138
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (15,000 KIU/kg)
Study: 9647138
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin with additional bolus
Study: 8702066
Drug: Early growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early growth modification treatment for Class II malocclusion (duration: 15 months)
Study: 343994
Drug: scopolamine-N-(cyclopropyl methyl)
Normalized name: (-)-scopolamine methyl bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine-N-(cyclopropyl methyl) bromide (DA 3177) at doses of 2.5 mg and 5 mg i.v.
Study: 343994
Drug: hyoscine-N-butyl bromide
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyoscine-N-butyl bromide at doses of 10 mg and 20 mg i.v.
Study: 28508114
Drug: L-menthol mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-menthol mouthwash
Study: 31654487
Drug: Evobrutinib (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib (single dose: 25, 50, 100, 200, 350, and 500 mg)
Study: 31654487
Drug: Evobrutinib (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib (multiple dosing: 25, 75, and 200 mg/day for 14 days)
Study: 31654487
Drug: Evobrutinib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib (≥ 200 mg single dose)
Study: 31654487
Drug: Evobrutinib (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib (≥ 100 mg)
Study: 31654487
Drug: Evobrutinib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib (25 mg multiple dosing)
Study: 29105625
Drug: Jin'gangteng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin'gangteng capsule combined with Kangfuxiaoyan suppository
Study: 29105625
Drug: Kangfuxiaoyan suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuxiaoyan suppository
Study: 23413101
Drug: Omalizumab 150
Normalized name: omalizumab 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 150 to 375 mg subcutaneously every 2 or 4 weeks from week 0 to 48
Study: 19231138
Drug: 5mg intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg intranasal diazepam (DZP)
Study: 19231138
Drug: 10mg intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg intranasal diazepam (DZP)
Study: 19231138
Drug: 5mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg intravenous diazepam (DZP injectable, 5mg/mL)
Study: 17268414
Drug: Herring diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herring diet (150 g baked herring fillets/day, 5 days/week)
Study: 9382049
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg a day for 1 month and amoxycillin 1 g three times daily for 14 days
Study: 8369641
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg d,l‐fenfluramine (FEN)
Study: 6145027
Drug: UK-38,485 (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-38,485 (specific thromboxane synthetase inhibitor)
Study: 31609920
Drug: Conditioned group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned group (oxytocin nasal spray with a distinctive smell)
Study: 31609920
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo spray)
Study: 31609920
Drug: Drug control
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug control group (oxytocin spray)
Study: 30757911
Drug: Linfadren® plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linfadren® plus conventional treatment
Study: 25331203
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with bupivacaine at a dose of 2.5 mg · kg(‐1)
Study: 25331203
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with bupivacaine at a dose of 1.25 mg · kg(‐1)
Study: 18268396
Drug: Interferon-alpha2a (IFN-alpha2a)
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a (IFN-alpha2a) administered for 6 days starting 1 week before nephrectomy.
Study: 18268396
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with IFN-alpha2a).
Study: 17133610
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone and 6 infusions (monthly) of intravenous cyclophosphamide (CYC) followed by oral azathioprine (AZA)
Study: 8857479
Drug: simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 10 mg bid
Study: 1629507
Drug: Budesonide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (600 micrograms, twice daily)
Study: 1629507
Drug: Terbutaline (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (375 micrograms, twice daily)
Study: 6860201
Drug: 0.125% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% betaxolol ophthalmic solution
Study: 16687979
Drug: Placebo (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (drug vehicle)
Study: 31919749
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil plus Chinese medicine (Tiaogan Jianpi Hexue and Tiaogan Jiedu Huashi)
Study: 30691922
Drug: Intracameral 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral 0.5% moxifloxacin (0.03 mL, 150 μg)
Study: 30691922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IC medication)
Study: 28513523
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy for 2 weeks
Study: 28513523
Drug: Bismuth containing
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth containing quadruple therapy for 2 weeks
Study: 28513523
Drug: 5 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 + 5 clarithromycin‐based sequential therapy
Study: 28513523
Drug: 7 +
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 + 7 clarithromycin‐based sequential therapy
Study: 26037777
Drug: Tocilizumab discontinuation
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab discontinuation
Study: 21644315
Drug: Moxibustion pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion pretreatment (mild moxibustion applied at Guanyuan (CV 4), Zusanli (ST 36) or Guanyuan (CV 4), Sanyinjiao (SP 6) alternatively once daily for 4 weeks)
Study: 20108857
Drug: Intramuscular pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pressure (IMP) during isometric fatiguing extension at 60% of maximum voluntary contraction
Study: 15288698
Drug: L‐NMMA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA infusion
Study: 8290916
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin 70 mg/m2 and doxorubicin 30 mg/m2, 2 cycles with 3-week interval)
Study: 3565525
Drug: Workbook-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workbook-based occupational therapy program
Study: 26452230
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy
Study: 26468947
Drug: Lapatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib at 750 mg
Study: 26468947
Drug: Lapatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib at 1,000 mg
Study: 26468947
Drug: Lapatinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib at 1,250 mg
Study: 21227012
Drug: Controlled ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation (COH) using triptorelin 0.1 mg/day SC and recombinant FSH 150 - 300 IU/day
Study: 21227012
Drug: Modified natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified natural cycle (MNC) treatment using HMG 150 IU/day IM if serum oestradiol was ≤ 50 pg/ml
Study: 10382235
Drug: BIPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIPAP therapy (n = 47)
Study: 10382235
Drug: Unassisted oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unassisted oxygen therapy (n = 46)
Study: 2871492
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 million IU, one-hour infusion)
Study: 31549624
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet containing amlodipine and rosuvastatin
Study: 31549624
Drug: Individual tablets
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual tablets of amlodipine and rosuvastatin (reference drugs)
Study: 30032806
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) adjunctive therapy
Study: 24641638
Drug: Prophylactic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic epidural blood patch
Study: 24641638
Drug: Therapeutic epidural
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic epidural blood patch
Study: 8567109
Drug: Screening tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening tests including PSA serum determination, rectal examination, and transrectal ultrasonography.
Study: 29878867
Drug: CT-cetux-RT (cetuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-cetux-RT (cetuximab plus radiotherapy with concurrent carboplatin and fluorouracil)
Study: 23094708
Drug: MN-221 (bedoradrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-221 (bedoradrine sulfate) via intravenous infusion
Study: 20823434
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to nevirapine-based therapy (n = 96)
Study: 16273650
Drug: TPN supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN supplemented with 0.417 g L-alanyl-L-glutamine (Ala-Gln)/kg per day
Study: 16273650
Drug: Conventional TPN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TPN solution receiving 1.5 g amino acids/kg per day
Study: 11812714
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's at 20 mL/kg starting at the time of spinal block
Study: 11812714
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's at 20 mL/kg starting 20 min before spinal block
Study: 11812714
Drug: Placebo (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactated Ringer's solution at 1-2 mL/min)
Study: 7741778
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet formulation of tiracizine
Study: 2203300
Drug: FCE 22891
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE 22891 (oral prodrug of FCE 22101)
Study: 7048188
Drug: Benzocaine (7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine (7.5% in propylene glycol gel)
Study: 16904812
Drug: D2-dopamine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2-dopamine antagonist sulpiride during n-back working memory tasks
Study: 16368447
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (N-acetylcysteine 600 mg/d, vitamin E 300 mg/d, vitamin C 250 mg/d)
Study: 2692652
Drug: Epirubicin 20
Normalized name: epiRUBicin 200 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 20 mg weekly bolus injection
Study: 2692652
Drug: Epirubicin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 40 mg weekly bolus injection
Study: 2692652
Drug: Epirubicin 24-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 24-h infusion
Study: 31866533
Drug: Methylaminolevulinate (MAL)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL)‐based PDT in three sessions with a light dose of 90 J/cm2 delivered in a single fraction in each session (Group I)
Study: 31866533
Drug: Methylaminolevulinate (MAL)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL)‐based PDT in three sessions with the light dose delivered in three fractions (Group II)
Study: 19081156
Drug: 0.01% rh-PDGF-BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% rh-PDGF-BB gel
Study: 9203721
Drug: IPV followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV followed by OPV (sequential schedules)
Study: 9203721
Drug: Two IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two IPV doses followed by two OPV doses (optimal schedule)
Study: 9203721
Drug: Prior OPV
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior OPV doses (two or more)
Study: 7968593
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene for 12 consecutive cycles
Study: 3377156
Drug: oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral metoclopramide
Study: 30033117
Drug: Selective Internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Internal Radiation Therapy (SIRT) plus mFOLFOX6 chemotherapy
Study: 27536069
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg daily for 6 months
Study: 27536069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (PCOS without treatment)
Study: 25711607
Drug: Delayed-dose oral
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-dose oral rotavirus vaccine
Study: 25711607
Drug: Injectable polio
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable polio vaccine replacing one dose of oral polio vaccine
Study: 23865123
Drug: Ginger in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger in capsule form for 3 days
Study: 18258768
Drug: Group-based high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based high-intensity interval training program (aerobic, resistance, flexibility, and balance activities), twice per week for 16 weeks.
Study: 9228372
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 70 mg/kg, n=14
Study: 9228372
Drug: L-2-oxothiazolidine-4-carboxylate (Procysteine;
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-2-oxothiazolidine-4-carboxylate (Procysteine; OTZ) 63 mg/kg, n=17
Study: 31206400
Drug: High-fiber DASH
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber DASH diet (32 g/d)
Study: 30055723
Drug: Narrative-based language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative-based language intervention (NBLI) group therapy
Study: 30055723
Drug: Conventional speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional speech therapy (CST)
Study: 27022997
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (MI) group - healthy nutrition educational program in addition to a healthy daily meal
Study: 27022997
Drug: Environmental intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Environmental intervention group - received a healthy daily meal
Study: 25034548
Drug: Concurrent physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent physical training program (CPTP) consisting of running training in the Fatmax intensity zone and strength training (squats and bench presses); three 40‐minute sessions a week for 24 weeks
Study: 16289514
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg intravenous (i.v.) or oral
Study: 340137
Drug: salsalate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: salsalate (3 g/day)
Study: 7133973
Drug: indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin (75 mg/day)
Study: 30301829
Drug: AR‐V7+ patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR‐V7+ patients receiving taxane therapy (docetaxel or cabazitaxel)
Study: 30301829
Drug: ARv567es+ patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARv567es+ patients receiving taxane therapy
Study: 21775562
Drug: Fish-oil-based lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil-based lipid emulsion (FOLE) at a dose of 1 g · kg(‐1) · d(‐1) for ≥1 month
Study: 17383291
Drug: Carvedilol (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (up-titrated to 25 mg BID)
Study: 17383291
Drug: Enalapril (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (up-titrated to 20 mg BID) and spironolactone (25 mg QD)
Study: 8111946
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (5% with Tegaderm)
Study: 1098397
Drug: Practolol (beta-1-blocker)
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (beta-1-blocker)
Study: 1098397
Drug: Practolol +
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol + Salbutamol (beta-2-stimulating drug)
Study: 31711707
Drug: KP-10 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-10 (5 μg/kg body weight), injected once weekly for one month
Study: 30927509
Drug: Telephone consultations
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone consultations with physiotherapists involving education, advice, and prescription of a strengthening and physical activity program over 26 weeks.
Study: 26416154
Drug: Brimonidine gel
Normalized name: brimonidine Topical Gel
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine gel 0.33%
Study: 24249434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mitiglinide and sitagliptin
Study: 16460701
Drug: 3D surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D surface models of the CC
Study: 16460701
Drug: Statistical maps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical maps of the CC
Study: 15257792
Drug: Quinine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine treatment at 10 mg/kg thrice daily for 7 days
Study: 15257792
Drug: Quinine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine treatment at 10 mg/kg twice daily for 7 days
Study: 15257792
Drug: Quinine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine treatment at 15 mg/kg once daily for 7 days
Study: 11398082
Drug: APC 366
Normalized name: Recombinant human activated protein C (rH-APC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC 366 (5 mg)
Study: 2169077
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injection once daily)
Study: 29557230
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone effervescent tablet daily (Group A)
Study: 29557230
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg IM 17‐OHPC weekly (Group B)
Study: 27040576
Drug: Hyperuricemia (UA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemia (UA >7 mg/dl in men and >6 mg/dl in women)
Study: 27040576
Drug: Normouricemic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normouricemic patients (UA ≤7 mg/dl in men and ≤6 mg/dl in women)
Study: 18508198
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of ultrasound to the right supraspinatus trigger point